Behavioral Assessment Method Index
Ohio State University · with Nationwide Children's Hospital, Virginia Polytechnic Institute and State University · NCT07291479
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 4 mo–3 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 80
- US sites recruiting
- 1
- Study start
- July 7, 2023
- Record last updated
- December 18, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The overall goal of this study is to develop and improve assessment methods for children with and without perinatal arterial ischemic stroke (PAS)/hemiparetic cerebral palsy (HCP). The focus is on behaviors of the arms and hands and includes other domains of child development like fine motor, gross motor, language, cognition, and social-emotional skills. This study involves 1) the use of data, including video recordings, from "I-ACQUIRE - Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation" (NCT03910075) and 2) a prospective longitudinal observational data collection with a typically developing cohort using a comprehensive assessment battery (play, fine motor, gross motor, language, cognition, and social emotional skills). The current study is called the BAM Index. No intervention or treatment is provided as part of the BAM Index. The I-ACQUIRE study is an RCT that includes an intervention. The BAM index study is a use of data from the I-ACQUIRE cohorts and a prospective observational study of a typically developing cohort (children without stroke or cerebral palsy) over time. The results of this work will develop, test, refine, and validate a new methodology based on reach-and-grasp and other behaviors related to child development that will have profound and lasting impact on assessment and selection of treatment strategies for pediatric physical rehabilitation of children. The use and reuse of video technology is also well-suited to remote or virtual assessment. This proposal will add to our current knowledge by 1) yielding a psychometrically robust and alternative approach to measuring upper extremity function in children with stroke and/or hemiparetic cerebral palsy and 2) defining specific parameters about how to promote closer-to-normal upper extremity function in children with motor disability.
Being studied: Non interventional study
Conditions: Infant Development; Perinatal Stroke; Hemiparesis; Cerebral Palsy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Between 8 and 36 months old at baseline
- Full Term Birth (37 to 41 weeks gestation)
- Healthy development (meeting age-appropriate milestones)
Exclusion Criteria
- Diagnosed or suspected impairments (auditory, visual, cognitive or motor)
Recruiting US locations
The Ohio State University
Columbus, OH 43210
Site contact: Jill Heathcock, PhD · (614) 292-2397 · jill.heathcock@osumc.edu
Study contacts (from the official record)
- Jill Heathcock, PhD · (614) 292-2397 · jill.heathcock@osumc.edu
- Petra Sternberg, PhD · 614-572-5446 · petra.sternberg@osumc.edu
Similar studies in Ohio
All neurology studies in Ohio →- RecruitingHealthy volunteers
A Study to Evaluate the SENSE Device's Ability to Detect TBI
Sense Diagnostics, LLC
- Location
- Cincinnati, OH + 5 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Columbus, OH + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
[18F]PI-2620 Phase 3 Histopathological Study
Lantheus Biosciences Ltd.
- Location
- Beachwood, OH + 16 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Cincinnati, OH + 35 other US sites
- Eligibility basics
- Ages 18–65